Triple-Drug Polypill Cuts Recurrent Stroke Risk by 39% in Brain Bleed Survivors
A low-dose three-drug pill slashed recurrent stroke risk and improved blood pressure control in intracerebral hemorrhage survivors, a major RCT found.
Summary
A randomized trial called TRIDENT tested a polypill combining three blood pressure drugs at low doses in survivors of intracerebral hemorrhage — a dangerous type of stroke caused by bleeding in the brain. Patients taking the GMRx2 pill alongside their usual medications had significantly better blood pressure control and a 39% lower risk of recurrent stroke over about 2.5 years. The pill contains telmisartan, amlodipine, and indapamide. Average systolic blood pressure was 127 mmHg in the polypill group versus 138 mmHg in the placebo group. Only 35 patients needed treatment to prevent one stroke. The findings, published in the New England Journal of Medicine, suggest that simplified combination therapy could meaningfully reduce one of the deadliest consequences of surviving a brain bleed.
Detailed Summary
Intracerebral hemorrhage — bleeding directly into brain tissue — is one of the most lethal forms of stroke, and survivors face high risk of recurrence. Blood pressure control is the only proven strategy to reduce that risk, yet long-term BP management after ICH remains notoriously poor due to medication non-adherence, therapeutic inertia, and unclear treatment targets. The TRIDENT trial was designed to test whether a simple, low-dose combination pill could close that gap.
The trial randomized ICH survivors already on standard background therapy to either the GMRx2 polypill — containing telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg — or placebo. Over a median follow-up of 2.5 years, recurrent stroke occurred in 4.6% of polypill users versus 7.4% in the placebo group, representing a 39% relative risk reduction. Recurrent ICH specifically was cut by 60%, from 4.4% to 1.8%. The number needed to treat to prevent one stroke was just 35.
The benefit appears driven by meaningfully better blood pressure control. Average systolic BP was 127 mmHg in the polypill group versus 138 mmHg with placebo. At six months, nearly 50% of polypill patients had achieved a systolic BP below 130 mmHg, compared to just 26% on placebo. Prior research has shown each 10 mmHg drop in systolic BP reduces ICH risk by roughly 40%, which aligns with these results.
The findings were published in the New England Journal of Medicine and presented at the World Stroke Congress. Researchers and stroke organization leaders called the results a major advance, expressing hope that GMRx2 will receive regulatory approval globally.
Important caveats apply. A substantial number of participants dropped out early due to rising serum creatinine levels, meaning results may only reflect those who tolerate the combination well. The polypill is investigational and not yet approved. Clinicians should monitor kidney function carefully if this approach is eventually adopted.
Key Findings
- Polypill reduced recurrent stroke risk by 39% over 2.5 years versus placebo in ICH survivors
- Recurrent intracerebral hemorrhage specifically dropped 60% with the three-drug combination pill
- Average systolic BP was 127 vs 138 mmHg — a clinically meaningful 11 mmHg difference
- Only 35 patients needed treatment to prevent one recurrent stroke event
- Nearly 50% of polypill users hit systolic BP below 130 mmHg at 6 months vs 26% on placebo
Methodology
This is a news report summarizing a published randomized placebo-controlled trial (TRIDENT) appearing in the New England Journal of Medicine, a top-tier peer-reviewed journal. The trial was conducted by researchers at the George Institute for Global Health and included ICH survivors on background therapy, with a median follow-up of 2.5 years. Evidence quality is high given the RCT design and prestigious publication venue.
Study Limitations
The polypill (GMRx2) is investigational and not yet approved by any regulatory authority, limiting immediate clinical application. A notable proportion of participants dropped out due to elevated serum creatinine, so results may not generalize to all ICH survivors, particularly those with impaired kidney function. The article is a news summary and full trial data including subgroup analyses should be reviewed in the primary NEJM publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.